OWINGS MILLS, Md., July 21 Medifast, Inc. (NYSE: MED), a leading portion-controlled weight-loss program, today announced the launch of a new line of supplements, Essential1: Digestive Health. Medifast's Essential1: Digestive Health supports a healthy gut environment beneficial for weight loss and keeps the digestive system in optimal balance.
"Medifast's Essential1: Digestive Health supplements prime the body for weight loss by providing the right mix of probiotics and digestive enzymes to optimize digestion, nutrient absorption, and metabolism," said Lisa M. Davis, Ph.D., PA-C, C.N.S., L.D.N., Vice President of Research and Development, Medifast, Inc. "Since 70% of the immune system is in the digestive system, Medifast's Essential1: Digestive Health supports immunity by ensuring optimal digestive health and balance."
The health of the digestive system determines how the body absorbs nutrients essential to maintaining metabolism, immune system, and even moods. Aging, poor health, medications, and other factors can lead to declines in the amount of both "good" bacteria and digestive enzymes in the digestive system, but a daily dose of Essential1: Digestive Health can help to restore them.
The two customized pills in Essential1: Digestive Health provides a unique formulation of probiotics and natural digestive enzymes not available in retail stores. The probiotic capsule contains three strains of "good" bacteria (ones most commonly found in a healthy digestive tract) in a prebiotic medium, which feeds the good bacteria and allows it to flourish. Good bacteria are restored, and favorable conditions for keeping the "bad" bacteria under control are created. The capsule contains just the right amount of healthy bacteria. The enzyme tablet blends 14 natural digestive enzymes to help your body break down food more easily and with less intestinal gas and bloating as you incorporate more healthy foods into your diet.
Medifast's Essential1: Digestive Health supplements are effective for clients in any phase of the Medifast Program, including before and during the Medifast 5 & 1 Plan, as well as clients in transition and maintenance.
Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. Medifast has been recommended by over 20,000 doctors and used by over one million customers since 1980. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) a national network of physicians, and 4) medically supervised Medifast Weight Control Centers. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto http://www.choosemedifast.com.
Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast's believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
SOURCE Medifast, Inc.